1.14.11.54	medicine	ALKBH3 promoter CpG island hypermethylation is most frequent in Hodgkin lymphoma cell lines (44%; 4 of 9), followed by Burkitt lymphoma (38%; 5 of 13), other non-Hodgkin lymphoma cell lines (37%; 12 of 32), and anaplastic large cell lymphoma. ALKBH3 promoter hypermethylation is detected in detected in18% (14 of 80) of the primary Hodgkin lymphoma cases. ALKBH3 CpG island hypermethylation is associated with protein loss. ALKBH3 epigenetic silencing is also associated with COL1A2 and COL1A1 overexpression, whereas an unmethylated ALKBH3 CpG island is linked to the absence of collagen expression. ALKBH3 hypermethylation is associated with shorter overall survival in the studied Hodgkin lymphoma cohort	764375	
1.14.11.54	medicine	human adenocarcinomas and squamous cell carcinomas of the lung show overexpression of Alkbh3 and the percentage of cells positive for Alkbh3 also correlates statistically to recurrence-free survival in adenocarcinoma. Knockdown of Alkbh3 by siRNA transfection induces expression of p21WAF1/Cip1 and p27Kip1 in the human lung adenocarcinoma cell line A-549, resulting in cell cycle arrest, senescence and strong suppression of cell growth in vitro. In vivo, peritoneal tumour growth and dissemination is inhibited in nude mice, previously inoculated with the A-549 cell line, by intraperitoneal injection of Alkbh3 siRNA plus atelocollagen	737957	
1.14.11.54	medicine	the alteration of ALKBH3 expression regulates the cytokine CSF-1 mRNA stability. Actions of cytokine CSF-1 lead to poor prognosis in ovarian and breast cancers. Demethylation of m1A by ALKBH3 increases the half-life of CSF-1 mRNA without affecting the translation efficiency. Overexpression of ALKBH3 increases CSF-1 expression and the degree of cancer cell invasiveness without affecting cell proliferation or migration	764223	
1.14.11.54	medicine	the enzyme is a prostate cancer marker	742749